FCCC LOGO Faculty Publications
Kircher SM , Meeker CR , Nimeiri H , Geynisman DM , Zafar SY , Shankaran V , de Souza J , Wong YN
The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?
Value Health. 2016 Jan;19(1) :88-98
Back to previous list
Abstract
Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy.
Notes
Kircher, Sheetal M Meeker, Caitlin R Nimeiri, Halla Geynisman, Daniel M Zafar, S Yousuf Shankaran, Veena de Souza, Jonas Wong, Yu-Ning United States Value Health. 2016 Jan;19(1):88-98. doi: 10.1016/j.jval.2015.10.005. Epub 2015 Nov 26.